瀏覽海報時間

MP05-01: The prognostic impact of tumour architecture for upper urinary tract urothelial carcinoma: A propensity score-weighted analysis

MP05-02: PR-619, an inhibitor of deubiquitylating enzymes, reverses drug resistance in cisplatin-resistant urothelial carcinoma cells via suppression of c-myc

MP05-03: Small non-coding microRNAs (miRNAs) target hepatoma-derived growth factor (HDGF) as a novel therapeutic strategy for urothelial carcinoma

MP05-04: The attenuation of chloroquine and hydroxychloroquine on the invasive potential of bladder cancer by targeting MMP-2 expression

MP05-05: Cadherin-11 regulates cell pyroptosis and induces anti-tumor immunity through PD-L1 in bladder cancer

MP05-06: External validation of Likert scale for predicting non-muscle invasive bladder cancer, KCGMH experience

MP05-07: Hyperthermia inhibits chemotherapeutic drug resistance of bladder cancer cells through epithelial mesenchymal transition down-regulation

MP05-08: Anti-cancer effects and tumor marker role of glutathione s-transferase mu 5 in human bladder cancer

MP05-09: Glutathione s-transferase Mu 5 plays anti-tumor activity in bladder cancer cells

MP05-10: Results of Bevacizumab plus Erlotinib in Patients with Advanced Papillary Renal Cell Carcinoma (pRCC) Including Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) Syndrome-Associated RCC